Latest News

Entos Pharmaceuticals signs new collaboration agreement with biopharmaceutical company

Entos Pharmaceuticals Inc. (“Entos” or the “Company”), a healthcare biotechnology company focused on the development of next-generation nucleic acid-based therapies using their Fusogenix drug delivery platform, today announced it has entered into a research, development and collaboration agreement (“Agreement”) with a clinical stage biopharmaceutical company (“Partner”) focused on the development of novel therapeutic compounds targeting autoimmune and inflammatory diseases.

Source link




Related posts

Yellow-lens glasses do not improve night driving visibility, study finds

Newsemia

Exploring the connection between science and music

Newsemia

FDA approves less-invasive LVAD for advanced HF

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy